ResearcherNantong UniversityActive in the last 2 years

Dandan Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4041-5150; OpenAlex author ID A5046719780. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer. Co-author DOI 10.32604/or.2026.084396 ↗
Autophagy-targeted intervention synergized with pegaspargase: an innovative therapeutic paradigm for pancreatic cancer. Co-author DOI 10.1186/s12935-025-04074-5 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xuyao Zhang · 2 shared papers, 2025–2026 · strength 0.60
- Paper Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer. DOI 10.32604/or.2026.084396 ↗
- Paper Autophagy-targeted intervention synergized with pegaspargase: an innovative therapeutic paradigm for pancreatic cancer. DOI 10.1186/s12935-025-04074-5 ↗
Chunbin Wang · 2 shared papers, 2025–2026 · strength 0.60
- Paper Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer. DOI 10.32604/or.2026.084396 ↗
- Paper Autophagy-targeted intervention synergized with pegaspargase: an innovative therapeutic paradigm for pancreatic cancer. DOI 10.1186/s12935-025-04074-5 ↗
Zhiyi Min · 1 shared paper, 2026 · strength 0.32
- Paper Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer. DOI 10.32604/or.2026.084396 ↗
Zhe Ding · 1 shared paper, 2026 · strength 0.32
- Paper Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer. DOI 10.32604/or.2026.084396 ↗
Zhe Ding · 1 shared paper, 2025 · strength 0.28
- Paper Autophagy-targeted intervention synergized with pegaspargase: an innovative therapeutic paradigm for pancreatic cancer. DOI 10.1186/s12935-025-04074-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.